Evommune, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1841 PAGE MILL RD, PALO ALTO, CA, 94304
Mailing Address 1841 PAGE MILL RD, PALO ALTO, CA, 94304
Phone (650) 223-7745
Fiscal Year End 1231
EIN 850742575
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | December 22, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
IPO Filings
S-1 October 9, 2025
- Targeting a $90 billion market for chronic inflammation diseases with two mid-stage drugs (EVO756 and EVO301) aiming to address root causes.
- Experienced leadership team with prior FDA approval success and board members involved in successful IPOs.
Insider Trading
BUY 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.